Want to see DERM full AI Analyst Report?
Journey Medical Corp (DERM) Ratios
Journey Medical Corp Ratios
DERM's free cash flow for Q2 2026 was $-1.73M. For the 2026 fiscal year, DERM's free cash flow was increased by $0.00 and operating cash flow was $-1.73M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.79 | 1.37 | 1.35 | 1.16 | 1.64 |
| Quick Ratio | 1.53 | 0.96 | 1.10 | 0.95 | 1.45 |
| Cash Ratio | 0.64 | 0.58 | 0.66 | 0.48 | 0.95 |
| Solvency Ratio | -0.11 | -0.19 | 0.00 | -0.29 | -0.75 |
| Operating Cash Flow Ratio | -0.33 | -0.26 | 0.13 | -0.20 | -0.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -14.60 | 1.75 | -4.59 | -2.69 |
| Net Current Asset Value | $ 4.14M | $ -11.99M | $ -44.00K | $ -10.50M | $ 29.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.27 | 0.32 | 0.23 | 0.22 | 0.01 |
| Debt-to-Equity Ratio | 0.80 | 1.28 | 0.87 | 1.35 | 0.02 |
| Debt-to-Capital Ratio | 0.44 | 0.56 | 0.47 | 0.57 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.44 | 0.55 | 0.42 | 0.54 | 0.00 |
| Financial Leverage Ratio | 2.97 | 4.00 | 3.78 | 6.19 | 2.31 |
| Debt Service Coverage Ratio | -0.92 | -2.54 | 0.36 | -4.68 | -4.38 |
| Interest Coverage Ratio | -2.21 | -5.07 | -1.22 | -13.63 | -4.96 |
| Debt to Market Cap | 0.13 | 0.32 | 0.17 | 0.68 | 0.01 |
| Interest Debt Per Share | 1.19 | 1.39 | 1.07 | 1.43 | 0.46 |
| Net Debt to EBITDA | -0.39 | -0.64 | -5.05 | 0.39 | 1.47 |
| Profitability Margins | |||||
| Gross Profit Margin | 59.29% | 62.81% | 66.33% | 58.23% | 49.18% |
| EBIT Margin | -12.40% | -21.22% | -2.44% | -37.39% | -55.95% |
| EBITDA Margin | -5.38% | -14.96% | 2.43% | -31.47% | -51.90% |
| Operating Profit Margin | -13.21% | -24.36% | -2.62% | -37.35% | -55.25% |
| Pretax Profit Margin | -18.38% | -26.03% | -4.59% | -40.13% | -67.10% |
| Net Profit Margin | -18.48% | -26.14% | -4.87% | -40.22% | -69.68% |
| Continuous Operations Profit Margin | -18.48% | -26.14% | -4.87% | -40.22% | -69.68% |
| Net Income Per EBT | 100.53% | 100.42% | 106.08% | 100.21% | 103.86% |
| EBT Per EBIT | 139.15% | 106.83% | 175.21% | 107.44% | 121.44% |
| Return on Assets (ROA) | -12.08% | -18.28% | -5.01% | -28.17% | -45.22% |
| Return on Equity (ROE) | -35.89% | -73.11% | -18.93% | -174.47% | -104.64% |
| Return on Capital Employed (ROCE) | -14.30% | -30.35% | -5.93% | -71.79% | -76.36% |
| Return on Invested Capital (ROIC) | -14.27% | -29.88% | -5.44% | -66.53% | -74.87% |
| Return on Tangible Assets | -17.07% | -30.33% | -6.81% | -38.00% | -51.92% |
| Earnings Yield | -6.05% | -18.37% | -3.67% | -88.02% | -47.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.08 | 5.49 | 5.20 | 2.61 | 2.73 |
| Payables Turnover | 2.71 | 1.30 | 1.66 | 0.83 | 1.41 |
| Inventory Turnover | 2.62 | 1.45 | 2.61 | 2.17 | 3.25 |
| Fixed Asset Turnover | 557.28 | 282.08 | 783.97 | 389.78 | 709.37 |
| Asset Turnover | 0.65 | 0.70 | 1.03 | 0.70 | 0.65 |
| Working Capital Turnover Ratio | 2.92 | 4.07 | 6.23 | 3.37 | 3.15 |
| Cash Conversion Cycle | 180.35 | 38.22 | -10.27 | -130.94 | -13.71 |
| Days of Sales Outstanding | 175.74 | 66.53 | 70.17 | 139.76 | 133.62 |
| Days of Inventory Outstanding | 139.49 | 252.28 | 139.73 | 167.93 | 112.19 |
| Days of Payables Outstanding | 134.89 | 280.58 | 220.16 | 438.63 | 259.52 |
| Operating Cycle | 315.23 | 318.80 | 209.90 | 307.69 | 245.81 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.51 | -0.45 | 0.29 | -0.77 | -0.13 |
| Free Cash Flow Per Share | -0.51 | -0.45 | 0.01 | -1.91 | -0.70 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -0.61 | 1.05 | -0.68 | -0.22 |
| Capital Expenditure Coverage Ratio | 0.00 | -0.61 | 1.05 | -0.68 | -0.22 |
| Operating Cash Flow Coverage Ratio | -0.49 | -0.36 | 0.30 | -0.59 | -2.40 |
| Operating Cash Flow to Sales Ratio | -0.20 | -0.16 | 0.07 | -0.18 | -0.03 |
| Free Cash Flow Yield | -6.59% | -11.42% | 0.23% | -99.63% | -13.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.40 | -5.43 | -27.26 | -1.14 | -2.12 |
| Price-to-Sales (P/S) Ratio | 3.05 | 1.42 | 1.33 | 0.46 | 1.48 |
| Price-to-Book (P/B) Ratio | 5.93 | 3.98 | 5.16 | 1.98 | 2.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.18 | -8.75 | 437.58 | -1.00 | -7.65 |
| Price-to-Operating Cash Flow Ratio | -15.18 | -8.75 | 20.04 | -2.49 | -42.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.47 | -0.02 | 0.31 | 0.03 | 0.00 |
| Enterprise Value Multiple | -57.16 | -10.16 | 49.61 | -1.06 | -1.37 |
| Enterprise Value | 190.19M | 85.29M | 95.31M | 24.62M | 44.99M |
| EV to EBITDA | -57.16 | -10.16 | 49.61 | -1.06 | -1.37 |
| EV to Sales | 3.07 | 1.52 | 1.20 | 0.33 | 0.71 |
| EV to Free Cash Flow | -15.29 | -9.34 | 397.12 | -0.73 | -3.69 |
| EV to Operating Cash Flow | -15.29 | -9.34 | 18.19 | -1.82 | -20.63 |
| Tangible Book Value Per Share | 0.17 | -0.58 | 0.00 | -0.58 | 1.70 |
| Shareholders’ Equity Per Share | 1.30 | 0.98 | 1.12 | 0.97 | 2.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | -0.06 | -0.00 | -0.04 |
| Revenue Per Share | 2.53 | 2.75 | 4.34 | 4.20 | 3.65 |
| Net Income Per Share | -0.47 | -0.72 | -0.21 | -1.69 | -2.54 |
| Tax Burden | 1.01 | 1.00 | 1.06 | 1.00 | 1.04 |
| Interest Burden | 1.48 | 1.23 | 1.88 | 1.07 | 1.20 |
| Research & Development to Revenue | 0.01 | 0.18 | 0.10 | 0.15 | 0.26 |
| SG&A to Revenue | 0.72 | 0.72 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.10 | 0.11 | 0.03 | 0.06 | 0.04 |
| Income Quality | 1.09 | 0.62 | -1.36 | 0.46 | 0.05 |
Currency in USD
